Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month Low at $4.94

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price hit a new 52-week low on Tuesday . The company traded as low as $4.94 and last traded at $4.94, with a volume of 830436 shares. The stock had previously closed at $4.99.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on AUPH shares. Jefferies Financial Group decreased their price objective on shares of Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a research report on Friday, February 16th. Royal Bank of Canada decreased their price target on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Finally, Cantor Fitzgerald decreased their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Performance

The company has a current ratio of 5.50, a quick ratio of 4.99 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $724.55 million, a PE ratio of -9.28 and a beta of 1.37. The firm’s 50-day simple moving average is $6.40 and its two-hundred day simple moving average is $7.65.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The company had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $45.00 million. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. The company’s revenue was up 58.8% on a year-over-year basis. On average, equities research analysts expect that Aurinia Pharmaceuticals Inc. will post -0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AUPH. China Universal Asset Management Co. Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,798 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $30,000. Sunbelt Securities Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at $31,000. Tidemark LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $39,000. Finally, Geneos Wealth Management Inc. lifted its position in Aurinia Pharmaceuticals by 54.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,142 shares during the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.